Edit |   |
Antigenic Specificity | CD59, Human |
Clone | REA496 |
Host Species | Recombinant Human |
Reactive Species | human, nonhuman primate |
Isotype | IgG1 |
Format | Vio Bright FITC conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD59 Antibody, anti-human, Vio® Bright FITC, REAfinity™. Clone REA496 recognizes the human CD59 antigen, a 20 kDa LY-6 like protein, which regulates the action of the complement membrane attack complex on homologous cells. This glycoprotein is widely distributed on the membranes of human erythrocytes and leukocytes. CD59, also known as protectin, was observed in vascular endothelia throughout the body, in extravascular tissues, and was also found in ductal epithelia of pancreatic, biliary and salivary systems, bronchi, and kidney collecting ducts. Furthermore, CD59 is expressed in the epidermis and in the syncytiotrophoblast of placenta. | Additional information: Clone REA496 displays negligible binding to Fc receptors. | | |
Immunogen | n/a |
Other Names | MIC11, MSK21, Protectin, MAC-IP, MIRL, G344, HRF-20, HRF20, MAC-IP, MACIF |
Gene, Accession # | Gene ID: 966 |
Catalog # | 130-118-365 |
Price | $405 |
Order / More Info | CD59, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Davies, A. et al. (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170 (3): 637-654. | Philbrick, W. M. et al. (1990) The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur. J. Immunol. 20 (1): 87-92. | Meri, S. et al. (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65 (5): 532-537. |